60 Degrees Pharmaceuticals (SXTP) CEO Dow Buys $10K of Stock
Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, acquired 7,350 shares on June 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Geoffrey Dow, President and CEO at 60 Degrees Pharmaceuticals, Inc. ($SXTP), bought 7,350 shares at an average price of $1.38, worth about $10,143, on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SXTP is up 24.3% after 1 week, up 6.6% after 1 month and down 36.8% to date (from the $1.36 close on Jun 12, 2026).
SXTP
60 Degrees Pharmaceuticals, Inc.
Key Points
- Geoffrey Dow, President and CEO of 60 Degrees Pharmaceuticals, purchased 7,350 shares of the company's stock at an average price of $1.38 each on June 12, 2026.
- 60 Degrees Pharmaceuticals, trading under NasdaqCM: SXTP, has a market cap of approximately $3.96 million with shares recently trading at $1.49.
- Analysts from Ascendiant Capital and HC Wainwright & Co. maintain buy ratings with price targets ranging from $3.7 to $24.0.
Get $SXTP trade alerts by text
We text you when insiders, Congress or big funds trade $SXTP. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated 60 Degrees Pharmaceuticals, Inc. alert may contain errors. Disclosures
Geoffrey Dow, the President and CEO of 60 Degrees Pharmaceuticals, Inc., recently bought 7,350 shares of the company on June 12, 2026. The shares were purchased at an average price of $1.38 each, totaling $10,143. This insider transaction was not part of a pre-planned trading program.
Insider Buying and Selling at 60 Degrees Pharmaceuticals, Inc.
Geoffrey Dow has been actively buying shares of 60 Degrees Pharmaceuticals. Alongside his recent purchase, previous transactions include buying 9,670 shares at $0.80 each on December 15, 2025, and acquiring 3,613 shares at $0.92 each on December 11, 2025.
Other Institutional Activity in 60 Degrees Pharmaceuticals
Institutional investors have been adjusting their holdings in 60 Degrees Pharmaceuticals. Kathmere Capital Management, LLC increased its stake by 144,683 shares, bringing its total to 144,683 shares valued at approximately $253,195. UBS Group AG acquired 31,410 shares, now holding shares worth about $54,968. Geode Capital Management, LLC added 16,295 shares, reaching a total of 16,295 shares valued at $28,516. Barclays PLC and NewEdge Advisors, LLC also increased their holdings, with shares totaling 1,856 and 50, respectively.
60 Degrees Pharmaceuticals, Inc. Stock Up 55.9%
Shares of 60 Degrees Pharmaceuticals, traded under NasdaqCM: SXTP, were recently priced at $1.49. The company has a market capitalization of approximately $3.96 million. The stock has experienced a 52-week low of $1.22 and a high of $10.77. Its 50-day moving average is $1.59, while the 200-day moving average is $3.41. The company has a high beta of 2.652, indicating significant volatility compared to the market.
Recent Earnings
60 Degrees Pharmaceuticals reported revenue of $1.31 million, though it experienced a revenue decline of 36.8%. The company is not currently profitable, with a negative return on equity of -172.8%. The next earnings report is expected on August 12, 2025.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on 60 Degrees Pharmaceuticals. On May 22, 2026, Ascendiant Capital reaffirmed its buy rating with a price target of $3.7. HC Wainwright & Co. also maintained a buy rating, setting a high target of $24.0 on January 27, 2026. The consensus target price is $3.7, based on one analyst's opinion.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Washington, D.C. It focuses on developing and commercializing therapies for infectious diseases. The company offers Arakoda for malaria prevention and is working on therapies for COVID-19, babesiosis, and other diseases. Founded in 2010, it is led by CEO Dr. Geoffrey Stuart Dow.
Bottom Line
Geoffrey Dow's recent stock purchase reflects his confidence in 60 Degrees Pharmaceuticals. Investors often watch insider transactions for potential insights into company prospects. However, it's important to remember that insider trades are just one piece of the puzzle. The company's stock remains volatile, and its financial performance is under pressure, as indicated by recent earnings data.
Related Filing Alerts
Source: Geoffrey Dow's Form 4 filing on $SXTP (Jun 12, 2026). Find the original filing: SXTP Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts